Co-delivery of LETM1 and CTMP synergistically inhibits tumor growth in H-ras12V liver cancer model mice

Cancer Gene Therapy

Volumn 20, Issue 3, 2013, Pages 186-194

  Shin, J Y ^a   Chung, Y S ^a   Kang, B ^a   Jiang, H L ^b   Yu, D Y ^c   Han, K ^a   Chae, C ^a   Moon, J H ^a   Jang, G ^a,d   Cho, M H ^a,d  

^a Seoul National University   (South Korea)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

2A peptide; CTMP; GPCS; LETM1; liver cancer

Indexed keywords

GENE THERAPY AGENT; LEUCINE ZIPPER EF HAND CONTAINING TRANSMEMBRANE 1; PROTEIN CARBOXYL TERMINAL MODULATOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL SWELLING; CONTROLLED STUDY; DISEASE MODEL; GENE TARGETING; GENE THERAPY; LIVER CANCER; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; GENE ORDER; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PLASMIDS; POLYETHYLENEIMINE; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; THIOLESTER HYDROLASES; TUMOR BURDEN;

MUS;

EID: 84875224868     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.6     Document Type: Article

References (44)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31: 100-110.
2. Kota J, Chivukula RR, ODonnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
3. Young JL, Dean DA. Nonviral gene transfer strategies for the vasculature. Microcirculation 2002; 9: 35-50.
4. Kim JH, Minai-Tehrani A, Kim YK, Shin JY, Hong SH, Kim HJ et al. Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly (ethylene glycol)-chitosan-graft-spermine. Biomaterials 2012; 33: 1894-1902.
5. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
6. Szymczak AL, Vignali DAA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005; 5: 627-638.
7. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006; 147: 239-248.
8. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapyinduced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 1998; 12: 141-152.
9. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464.
10. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008; 18: 165-173.
11. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112: 481-490.
12. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev 2008; 22: 1577-1590.
13. Dimmer KS, Navoni F, Casarin A, Trevisson E, Endele S, Winterpacht A et al. LETM1, deleted in Wolf-Hirschhorn syndrome is required for normal mitochondrial morphology and cellular viability. Hum Mol Genet 2008; 17: 201-214.
14. Hwang SK, Piao L, Lim HT, Minai-Tehrani A, Yu KN, Ha YC et al. Suppression of lung tumorigenesis by leucine zipper/EF hand-containing transmembrane-1. PLoS ONE 2010; 5: e12535.
15. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001; 294: 374-380.
16. Piao L, Li Y, Kim SJ, Sohn KC, Yang KJ, Park KA et al. Regulation of OPA1-mediated mitochondrial fusion by leucine zipper/EF-hand-containing transmembrane protein-1 plays a role in apoptosis. Cell Signal 2009; 21: 767-777.
17. Hwang S, Kwon J, Park S, Chang S, Lee E, Chung Y et al. Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther 2007; 14: 1721-1730.
18. Hwang S, Minai-Tehrani A, Yu K, Chang S, Kim J, Lee K et al. Carboxyl-terminal modulator protein induces apoptosis by regulating mitochondrial function in lung cancer cells. Int J Oncol 2011; 40: 1515-1524.
19. Hwang SK, Lim HT, Minai-Tehrani A, Lee ES, Park J, Park SB et al. Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice. Am J Respir Crit Care Med 2009; 179: 1131-1140.
20. Wang AG, Moon HB, Lee MR, Hwang CY, Kwon KS, Yu SL et al. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol 2005; 43: 836-844.
21. Trichas G, Begbie J, Srinivas S. Use of the viral 2A peptide for bicistronic expression in transgenic mice. BMC Biol 2008; 6: 40.
22. Deng W, Yang D, Zhao B, Ouyang Z, Song J, Fan N et al. Use of the 2A peptide for generation of multi-transgenic pigs through a single round of nuclear transfer. PLoS ONE 2011; 6: e19986.
23. Hunter T. Oncoprotein networks. Cell 1997; 88: 333-346.
24. McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA. Factors affecting retroviral vector function and structural integrity. Virology 1993; 195: 1-5.
25. Xu L, Yee JK, Wolff J, Friedmann T. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 1989; 171: 331-341.
26. Gu M, Cooper J, Taanman J, Schapira A. Mitochondrial DNA transmission of the mitochondrial defect in Parkinsons disease. Ann Neurol 1998; 44: 177-186.
27. Schapira A, Cooper J, Dexter D, Clark J, Jenner P, Marsden C. Mitochondrial complex I deficiency in Parkinsons disease. J Neurochem 1990; 54: 823-827.
28. Brandon M, Baldi P, Wallace D. Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-4662.
29. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002; 1: 9.
30. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006; 25: 4663-4674.
31. Parcellier A, Tintignac LA, Zhuravleva E, Cron P, Schenk S, Bozulic L et al. Carboxyterminal modulator protein (CTMP) is a mitochondrial protein that sensitizes cells to apoptosis. Cell Signal 2009; 21: 639-650.
32. Marzo I, Brenner C, Zamzami N, Ju rgensmeier JM, Susin SA, Vieira HLA et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-2031.
33. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997; 139: 1281-1292.
34. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
35. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000; 60: 1645-1653.
36. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226.
37. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321: 161-167.
38. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71.
39. Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, Mu ller M et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol 2006; 28: 25-32.
40. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A et al. Elevated expression of endoglin, a component of the TGF-b-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999; 81: 568-572.
41. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD et al. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 2001; 98: 7481-7486.
42. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008.
43. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-1673.
44. Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 2000; 19: 1294-1303.